February 22, 2018
Nicole Harriott, director of chemistry of Neurocrine Biosciences, prepares a sample at a company lab as part of the drug discovery and development process. Neurocrine banked on the neuroscience, which has paid off. Photo courtesy of Neurocrine Bioscienes
Stories this photo appears in:
MEDICINE: Big Players Bail, But Midsize Cos. Aim for Next Big Thing
Amid big pharma’s waning commitment to neurological disorders like Alzheimer’s, San Diego startups and midstage biotechs see opportunity.